EP3842064A1 - Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique - Google Patents
Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique Download PDFInfo
- Publication number
- EP3842064A1 EP3842064A1 EP19219342.3A EP19219342A EP3842064A1 EP 3842064 A1 EP3842064 A1 EP 3842064A1 EP 19219342 A EP19219342 A EP 19219342A EP 3842064 A1 EP3842064 A1 EP 3842064A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- allergen
- use according
- pbmcs
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 28
- 230000007815 allergy Effects 0.000 title claims abstract description 28
- 208000030961 allergic reaction Diseases 0.000 title claims abstract description 11
- 239000013566 allergen Substances 0.000 claims abstract description 118
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 41
- 241000124008 Mammalia Species 0.000 claims abstract description 37
- 239000006228 supernatant Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 238000007910 systemic administration Methods 0.000 claims abstract description 11
- 238000004113 cell culture Methods 0.000 claims abstract description 9
- 239000002609 medium Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 230000005865 ionizing radiation Effects 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000013570 bacterial allergen Substances 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 229960004784 allergens Drugs 0.000 description 52
- 210000003630 histaminocyte Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 15
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229920002055 compound 48/80 Polymers 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 5
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 244000000231 Sesamum indicum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 206010003402 Arthropod sting Diseases 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013568 food allergen Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010083391 glycinin Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- -1 pollen Substances 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108010001724 wheat omega-5 gliadin Proteins 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
Definitions
- allergens professional antigen-presenting cells phagocytose antigens (with regard to allergies referred to as allergens) and cross-present processed antigens to T H 2 lymphocytes. These cells respond to allergen-encounter by release of interleukin 4 and interact with B lymphocytes. Activated B cells, together with IL-4, produce type E immunoglobulins (IgE) directed against the allergen. Secreted IgE is bound by IgE-specific receptors present on, e.g., mast cells. These immune cells are thereby sensitized to the allergen. Re-exposure results in binding of the allergen to IgE-coated immune cells, which, after receptor crosslinking, causes activation of sensitized cells.
- IgE-specific receptors present on, e.g., mast cells.
- Animal allergens are allergens that include one or more compounds found in animals, including both vertebrates and invertebrates.
- Vertebrate animal allergens that may be present in mixed allergen compositions include avian allergens, such as egg allergens, e.g., nGal d 1 Ovomucoid, n Gal d 2 Ovalbumin, nGal d 3 Conalbumin, egg white complete allergen, etc.; mammalian allergens, such as milk allergens, e.g., nBos d 4 alpha-lactalbumin, nBos d 5 beta-lactoglobulin, nBos d 8 Casein, nBos d Lactoferrin, milk complete allergen, etc.; fish allergens, e.g., rCyp c 1, rGad c 1, cod complete allergen, white fish allergens, pink fish allergens, etc.
- the stress inducing condition is selected from the group consisting of radiation, in particular ionizing radiation or UV radiation, hypoxia, ozone, heat, osmotic pressure and pH shift.
- a further aspect of the present invention relates to a method for determining the suitability of a composition as defined above to be used in the treatment or prevention of an allergy or allergic reactions caused by an uptake of at least one allergen to a human or mammal body comprising the steps of
- Example 2 Alleviated symptoms of allergic hypersensitivity by application of Aposec in vivo
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19219342.3A EP3842064A1 (fr) | 2019-12-23 | 2019-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
| CA3161094A CA3161094A1 (fr) | 2019-12-23 | 2020-12-23 | Composition de traitement ou de prevention d'allergie ou de reaction allergique |
| AU2020415329A AU2020415329A1 (en) | 2019-12-23 | 2020-12-23 | Composition for treating or preventing an allergy or allergic reaction |
| KR1020227021365A KR20220119039A (ko) | 2019-12-23 | 2020-12-23 | 알레르기 또는 알레르기 반응의 치료 또는 예방용 조성물 |
| JP2022538264A JP2023507518A (ja) | 2019-12-23 | 2020-12-23 | アレルギー又はアレルギー反応を処置又は予防するための組成物 |
| US17/782,801 US20230000910A1 (en) | 2019-12-23 | 2020-12-23 | Composition for treating or preventing an allergy or allergic reaction |
| BR112022011976A BR112022011976A2 (pt) | 2019-12-23 | 2020-12-23 | Composição para tratar ou prevenir uma alergia ou reação alérgica |
| CN202080089704.4A CN115023235A (zh) | 2019-12-23 | 2020-12-23 | 用于治疗或预防过敏或过敏反应的组合物 |
| PCT/EP2020/087757 WO2021130305A1 (fr) | 2019-12-23 | 2020-12-23 | Composition de traitement ou de prévention d'allergie ou de réaction allergique |
| EP20839094.8A EP4081246B1 (fr) | 2019-12-23 | 2020-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19219342.3A EP3842064A1 (fr) | 2019-12-23 | 2019-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3842064A1 true EP3842064A1 (fr) | 2021-06-30 |
Family
ID=69061128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19219342.3A Withdrawn EP3842064A1 (fr) | 2019-12-23 | 2019-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
| EP20839094.8A Active EP4081246B1 (fr) | 2019-12-23 | 2020-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20839094.8A Active EP4081246B1 (fr) | 2019-12-23 | 2020-12-23 | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230000910A1 (fr) |
| EP (2) | EP3842064A1 (fr) |
| JP (1) | JP2023507518A (fr) |
| KR (1) | KR20220119039A (fr) |
| CN (1) | CN115023235A (fr) |
| AU (1) | AU2020415329A1 (fr) |
| BR (1) | BR112022011976A2 (fr) |
| CA (1) | CA3161094A1 (fr) |
| WO (1) | WO2021130305A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4197547A1 (fr) * | 2021-12-20 | 2023-06-21 | Aposcience AG | Composition pour le traitement ou la prévention de la vasculite et des maladies associées à la vasculite |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070105A1 (fr) | 2008-12-18 | 2010-06-24 | Aposcience Ag | Préparation pharmaceutique |
| WO2010079086A1 (fr) | 2008-12-18 | 2010-07-15 | Aposcience Ag | Préparation pharmaceutique comprenant un surnageant de culture cellulaire mononucléaire de sang |
| WO2019121989A1 (fr) * | 2017-12-20 | 2019-06-27 | Aposcience Ag | Essai de puissance de sécrétomes |
-
2019
- 2019-12-23 EP EP19219342.3A patent/EP3842064A1/fr not_active Withdrawn
-
2020
- 2020-12-23 AU AU2020415329A patent/AU2020415329A1/en active Pending
- 2020-12-23 CN CN202080089704.4A patent/CN115023235A/zh active Pending
- 2020-12-23 US US17/782,801 patent/US20230000910A1/en active Pending
- 2020-12-23 CA CA3161094A patent/CA3161094A1/fr active Pending
- 2020-12-23 BR BR112022011976A patent/BR112022011976A2/pt unknown
- 2020-12-23 JP JP2022538264A patent/JP2023507518A/ja active Pending
- 2020-12-23 WO PCT/EP2020/087757 patent/WO2021130305A1/fr active Application Filing
- 2020-12-23 EP EP20839094.8A patent/EP4081246B1/fr active Active
- 2020-12-23 KR KR1020227021365A patent/KR20220119039A/ko unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070105A1 (fr) | 2008-12-18 | 2010-06-24 | Aposcience Ag | Préparation pharmaceutique |
| WO2010079086A1 (fr) | 2008-12-18 | 2010-07-15 | Aposcience Ag | Préparation pharmaceutique comprenant un surnageant de culture cellulaire mononucléaire de sang |
| WO2019121989A1 (fr) * | 2017-12-20 | 2019-06-27 | Aposcience Ag | Essai de puissance de sécrétomes |
Non-Patent Citations (13)
| Title |
|---|
| BEER LUCIAN ET AL: "Peripheral blood mononuclear cell secretome for tissue repair", APOPTOSIS, LONDON, GB, vol. 21, no. 12, 1 October 2016 (2016-10-01), pages 1336 - 1353, XP036085112, ISSN: 1360-8185, [retrieved on 20161001], DOI: 10.1007/S10495-016-1292-8 * |
| CARL HARRELL ET AL: "Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome", CELLS, vol. 8, no. 5, 16 May 2019 (2019-05-16), pages 467, XP055701139, DOI: 10.3390/cells8050467 * |
| HAIDER T ET AL., EXP NEUROL., vol. 267, 2015, pages 230 - 42 |
| HAK SUN YU ET AL: "Culture supernatant of adipose stem cells can ameliorate allergic airway inflammation via recruitment of CD4+CD25+Foxp3 T cells", STEM CELL RESEARCH & THERAPY, vol. 8, no. 1, 23 January 2017 (2017-01-23), XP055701050, DOI: 10.1186/s13287-016-0462-5 * |
| LEE NA RAE ET AL: "Cytokine secreted by S100A9 via TLR4 in monocytes delays neutrophil apoptosis by inhibition of caspase 9/3 pathway", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 86, 25 July 2016 (2016-07-25), pages 53 - 63, XP029682223, ISSN: 1043-4666, DOI: 10.1016/J.CYTO.2016.07.005 * |
| LICHTENAUER MICHAEL ET AL: "Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study", BASIC RESEARCH IN CARDIOLOGY, STEINKOPFF-VERLAG, DA, vol. 106, no. 6, 1 November 2011 (2011-11-01), pages 1283 - 1297, XP002777988, ISSN: 1435-1803 * |
| LUCIAN BEER ET AL: "Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration", SCIENTIFIC REPORTS, vol. 5, no. 1, 16 November 2015 (2015-11-16), XP055589420, DOI: 10.1038/srep16662 * |
| MARIA LAGGNER ET AL: "Therapeutic potential of lipids obtained from [gamma]-irradiated PBMCs in dendritic cell-mediated skin inflammation", EBIOMEDICINE, vol. 55, 1 May 2020 (2020-05-01), pages 102774, XP055703846, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2020.102774 * |
| MARTINE HEYMAN ET AL: "Mononuclear cells from infants allergic to cow's milk secrete tumor necrosis factor [alpha], altering intestinal function", GASTROENTEROLOGY, vol. 106, no. 6, 1 June 1994 (1994-06-01), US, pages 1514 - 1523, XP055701022, ISSN: 0016-5085, DOI: 10.1016/0016-5085(94)90405-7 * |
| MONICA BAIULA ET AL: "Mesenchymal stem cell secretome to control inflammation in allergic conjunctivitis", EYE SCI, 1 January 2015 (2015-01-01), pages 140 - 142, XP055701183, Retrieved from the Internet <URL:https://ykxb.amegroups.com/article/view/3531/4229> [retrieved on 20200604], DOI: 10.3978/j.issn.1000-4432.2015.11.18 * |
| TANJA WAGNER ET AL: "Different pro-angiogenic potential of [gamma]-irradiated PBMC-derived secretome and its subfractions", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 December 2018 (2018-12-01), XP055589646, DOI: 10.1038/s41598-018-36928-6 * |
| THOMAS HAIDER ET AL: "The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats", EXPERIMENTAL NEUROLOGY, vol. 267, 1 May 2015 (2015-05-01), AMSTERDAM, NL, pages 230 - 242, XP055700864, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2015.03.013 * |
| WAGNER T ET AL., SCI REP., vol. 8, no. 1, 2018, pages 18016 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4197547A1 (fr) * | 2021-12-20 | 2023-06-21 | Aposcience AG | Composition pour le traitement ou la prévention de la vasculite et des maladies associées à la vasculite |
| WO2023118219A1 (fr) * | 2021-12-20 | 2023-06-29 | Aposcience Ag | Composition pour le traitement ou la prévention de la vascularite et des maladies associées à la vascularite |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021130305A1 (fr) | 2021-07-01 |
| US20230000910A1 (en) | 2023-01-05 |
| BR112022011976A2 (pt) | 2022-08-30 |
| CA3161094A1 (fr) | 2021-07-01 |
| KR20220119039A (ko) | 2022-08-26 |
| EP4081246B1 (fr) | 2024-04-10 |
| JP2023507518A (ja) | 2023-02-22 |
| AU2020415329A1 (en) | 2022-06-09 |
| EP4081246A1 (fr) | 2022-11-02 |
| CN115023235A (zh) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rustemeyer et al. | Mechanisms of allergic contact dermatitis | |
| Hu et al. | Hydrogen sulfide inhalation-induced immune damage is involved in oxidative stress, inflammation, apoptosis and the Th1/Th2 imbalance in broiler bursa of Fabricius | |
| Machado et al. | Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen‐specific IgE | |
| US20190038741A1 (en) | Mixed allergen compositions and methods for using the same | |
| Yang et al. | Schistosoma japonicum egg antigens stimulate CD4+ CD25+ T cells and modulate airway inflammation in a murine model of asthma | |
| JP2813467B2 (ja) | 細胞培養法および培地 | |
| Ruiz-Argüelles et al. | Apoptosis of melanocytes in vitiligo results from antibody penetration | |
| Kim et al. | Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: Role of dendritic cells | |
| TWI449530B (zh) | 免疫調節物、包含免疫調節物之製備物與組成物、評估免疫調節物及包含其之製備物和組成物之活性的試驗及方法 | |
| AU2009208390B2 (en) | A method of inducing tolerance to an allergen | |
| JP4804626B2 (ja) | 免疫レギュレータ | |
| EP4081246B1 (fr) | Composition de traitement ou de prévention d'une allergie ou d'une réaction allergique | |
| AU2003250892A1 (en) | Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors | |
| Young et al. | Allogeneic and autologous telomerase-positive stem cells as a potential treatment for systemic lupus erythematosus | |
| JP2009518387A (ja) | 免疫反応を調節する組成物および方法 | |
| CN102441159B (zh) | 一种人类多肽在制备免疫调节剂中的应用 | |
| KR20160013275A (ko) | 장염 병태의 치료용 조성물 | |
| Schumacher et al. | Aqueous extract of Passiflora alata leaves modulates in vitro the indoleamine 2, 3-dioxygenase (IDO) and CD86 expression in bone marrow-derived professional antigen-presenting cells polarizing NOD mice T cells to a Treg profile | |
| Pinheiro et al. | Neospora caninum: infection induced IL-10 overexpression in rat astrocytes in vitro | |
| Lee et al. | Vibrio vulnificus infection induces the maturation and activation of dendritic cells with inflammatory Th17-polarizing ability | |
| DE19726255C2 (de) | Beeinflussung von Cytokinen durch proteolytische Enzyme und Rutosid | |
| KR102173640B1 (ko) | 역분화 줄기세포 유래 중간엽 줄기세포를 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
| EP3493835B1 (fr) | Méthode d'induction ex vivo de lymphocytes suppresseurs à l'aide de protéines provenant de parasites d'helminthes | |
| EP0950065B1 (fr) | Peptides servant d'agent diagnostique et d'agent therapeutique pour les maladies auto-immunes | |
| WO1999064066A1 (fr) | Agents induisant une tolerance immunitaire et contenant de la keratine dure ou une substance ressemblant a la keratine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20220104 |